STOCK TITAN

Caribou Biosciences (CRBU) Stock News, May-Nov 2022

CRBU NASDAQ

Caribou Biosciences develops CRISPR genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies. Company updates center on vispacabtagene regedleucel, or vispa-cel, an anti-CD19 CAR-T therapy being evaluated in B cell non-Hodgkin lymphoma and large B cell lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.

Recurring announcements include clinical and translational data from the ANTLER and CaMMouflage trials, FDA designations and trial-design interactions, financial results, research and development spending, cash resources, pipeline prioritization, and medical or investor conference participation.

Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) announced FDA has granted its CB-010 therapy both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). This therapy, the first allogeneic CAR-T with a PD-1 knockout, is undergoing the ANTLER Phase 1 trial. Three out of six patients had a durable complete response at six months. These designations aim to expedite development and regulatory review for promising treatments addressing significant patient needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
-
Rhea-AI Summary

Caribou Biosciences (CRBU) reported its Q3 2022 results, highlighting a strong financial position with $342.6 million in cash and marketable securities. The ANTLER Phase 1 trial for its lead therapy, CB-010, shows promising early safety and efficacy data for r/r B-NHL patients, with plans to share additional results by year-end. The company submitted an IND application for CB-011 targeting r/r MM and expects further milestones, including CB-020 target selection, in the upcoming months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
-
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) announced its participation in several upcoming investor conferences. Key events include:

  • Barclays Gene Editing & Gene Therapy Summit on November 14, 2022
  • Jefferies London Healthcare Conference on November 17, 2022
  • 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022
  • BofA Securities Biotech SMID Cap Conference on December 7, 2022

Webcasts of these presentations will be available for 30 days post-event on Caribou's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.10%
Tags
conferences
Rhea-AI Summary

Caribou Biosciences, Inc. (Nasdaq: CRBU) announced that its trial-in-progress abstract for the ANTLER Phase 1 clinical trial of CB-010, targeting relapsed or refractory B cell non-Hodgkin lymphoma, has been accepted for a poster presentation at the 64th ASH Annual Meeting from December 10-13, 2022, in New Orleans.

The presentation, by Dr. Susan O’Brien, will detail the trial design and objectives. CB-010 is an allogeneic CAR-T cell therapy employing CRISPR technology. The poster will be accessible on the ASH website and Caribou's website following the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
conferences
-
Rhea-AI Summary

Caribou Biosciences has reported a 15-month complete response in the first patient treated with CB-010 for relapsed or refractory aggressive B cell non-Hodgkin lymphoma. This case, presented at the Lymphoma, Leukemia, & Myeloma Congress, shows promising results following a single dose of CB-010. The patient, previously heavily treated, achieved and maintained a complete response since 28 days post-treatment. Caribou is advancing the ANTLER Phase 1 trial, now enrolling patients at a higher dose level, aiming to enhance the therapy's efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
-
Rhea-AI Summary

Caribou Biosciences, a clinical-stage CRISPR genome-editing biopharmaceutical company, announced its participation in several upcoming investor conferences. Significant events include:

  • Citi 17th Annual BioPharma Conference on September 8, 2022, at 11:20 am ET
  • H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 10:00 am ET
  • Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 4:40 pm ET
  • Jefferies Cell and Genetic Medicines Summit on September 29-30, 2022

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
conferences
Rhea-AI Summary

Caribou Biosciences (CRBU) reported significant progress in its clinical pipeline and a strong financial position with $366.1 million in cash as of June 30, 2022. The company achieved a 100% complete response rate in its CB-010 ANTLER Phase 1 trial for relapsed or refractory B cell non-Hodgkin lymphoma. Plans include enrolling more patients and submitting IND applications for CB-011 and CB-012 in late 2022 and 2023, respectively. Revenue from licensing and collaborations increased significantly, but R&D and G&A expenses also rose, leading to a net loss of $26.7 million for Q2 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.25%
Tags
-
Rhea-AI Summary

Caribou Biosciences (CRBU) reported promising results from its ANTLER Phase 1 trial for CB-010, an allogeneic CAR-T cell therapy. A 100% complete response (CR) rate was observed in six patients following a single dose, with 40% maintaining CR at six months. The first patient treated remained in CR for 12 months. The trial is now enrolling at a higher dosage, reflecting an initial positive safety profile and clinical activity. Additional data is expected by year-end 2022, suggesting potential advancements in CRISPR-edited therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.41%
Tags
-
Rhea-AI Summary

Caribou Biosciences, Inc. (Nasdaq: CRBU) will present additional clinical data from its ANTLER Phase 1 trial of CB-010, a CRISPR-edited CAR-T cell therapy for relapsed/refractory B cell non-Hodgkin lymphoma, during a webcast on June 10, 2022. The presentation will feature longer duration data from six patients treated at dose level 1. The live webcast begins at 8:00 am ET, and the poster will be showcased at the European Hematology Association 2022 Congress in Vienna. CB-010 represents a novel approach with a PD-1 knockout design aimed at enhancing antitumor activity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
conferences clinical trial
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) presented studies at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) on May 16, 2022, showcasing the enhanced specificity of its CRISPR hybrid RNA-DNA (chRDNA) guides for genome editing. Dr. Steve Kanner highlighted that these guides improve the efficacy and persistence of allogeneic cell therapies by minimizing off-target activities. The optimized chRDNA guides demonstrate superior precision in editing primary human T cells, reinforcing their potential in therapeutic applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none

FAQ

What is the current stock price of Caribou Biosciences (CRBU)?

Caribou Biosciences (CRBU) last closed at $0.2843.

What is the market cap of Caribou Biosciences (CRBU)?

The market cap of Caribou Biosciences (CRBU) is approximately $30.7M.